Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Optune Clear all
Completed Phase 2 Interventional Results available

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

NCT01894061
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
Bevacizumab, NovoTTF-l00A, Quality of Life Assessment
Biological · Device · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 2, 2026, 5:27 AM EDT
Withdrawn Phase 2 Interventional

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

NCT02348255
View directory record Official record
Conditions
Adult Brain Glioblastoma, Recurrent Adult Brain Neoplasm
Interventions
Electric Field Therapy, Bevacizumab, Carmustine, Quality-of-Life Assessment
Procedure · Biological · Drug + 1 more
Lead sponsor
University of California, Davis
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Sacramento, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 2, 2026, 5:27 AM EDT
Recruiting Phase 3 Interventional

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563
View directory record Official record
Conditions
Glioblastoma
Interventions
Optune® device, Temozolomide, Pembrolizumab, Placebo
Device · Drug
Lead sponsor
NovoCure GmbH
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 5:27 AM EDT
Active, not recruiting Phase 1 Interventional

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

NCT03223103
View directory record Official record
Conditions
Glioblastoma
Interventions
Poly-ICLC, Tumor Treating Fields, Peptides
Drug · Device · Biological
Lead sponsor
Adilia Hormigo
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 2, 2026, 5:27 AM EDT
Completed No phase listed Observational

NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy

NCT03194971
View directory record Official record
Conditions
Glioblastoma
Interventions
Tumor samples from patients treated with TTFields at initial diagnosis., Tumor samples from patients treated with TTFields at tumor recurrence.
Other · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 2, 2026, 5:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

NCT04396860
View directory record Official record
Conditions
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
Procedure · Biological · Device + 3 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
285
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 2, 2026, 5:27 AM EDT
Completed Phase 1 Interventional

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

NCT04757662
View directory record Official record
Conditions
Grade III Astrocytoma, Grade IV Astrocytoma, Astrocytoma, Grade IV, Astrocytoma, Grade III
Interventions
Tadalafil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 2, 2026, 5:27 AM EDT
Completed Phase 3 Interventional

Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

NCT00379470
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
NovoTTF-100A
Device
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
15
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 2, 2026, 5:27 AM EDT
Completed Early Phase 1 Interventional

Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

NCT03477110
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Radiation Therapy, NovoTTF-200A Device, Tumor Treating Fields Therapy
Drug · Radiation · Device + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 2, 2026, 5:27 AM EDT
Terminated Not applicable Interventional

NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01954576
View directory record Official record
Conditions
Glioblastoma, Brain Neoplasms
Interventions
NovoTTF-100A, Quality-of-life assessment, Laboratory biomarker analysis
Device · Procedure · Genetic
Lead sponsor
University of Florida
Other
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 2, 2026, 5:27 AM EDT
Active, not recruiting No phase listed Observational

Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI

NCT03297125
View directory record Official record
Conditions
Glioblastoma
Interventions
Standard Magnetic Resonance Imaging (MRI), Advanced MRI.
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 2, 2026, 5:27 AM EDT
Completed Phase 1 Interventional

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

NCT04474353
View directory record Official record
Conditions
Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
Optune, Gadolinium, Temozolomide, Stereotactic radiosurgery (SRS)
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 2, 2026, 5:27 AM EDT
Terminated No phase listed Observational

Prognosis and Therapeutic Biomarkers for Glioblastoma Patients

NCT03403803
View directory record Official record
Conditions
Glioblastoma
Interventions
Optune
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 2, 2026, 5:27 AM EDT
Terminated Phase 4 Interventional

Post-approval Study of NovoTTF-100A in Recurrent GBM Patients

NCT01756729
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
NovoTTF-100A
Device
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
22 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 2, 2026, 5:27 AM EDT
Recruiting Not applicable Interventional

Tumor Treating Fields for the Treatment of Brainstem Gliomas

NCT05310448
View directory record Official record
Conditions
Glioma
Interventions
Optune device
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 2, 2026, 5:27 AM EDT
Recruiting Phase 2 Interventional

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

NCT02847559
View directory record Official record
Conditions
Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
Interventions
Bevacizumab, Electric Field Therapy, NovoTTF-200A Device, Quality-of-Life Assessment
Biological · Procedure · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Santa Monica, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 2, 2026, 5:27 AM EDT
Terminated Phase 2 Interventional Results available

Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

NCT02743078
View directory record Official record
Conditions
Glioblastoma, Glioma, Gliosarcoma
Interventions
Bevacizumab, TTFields Therapy
Drug · Device
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
22 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
La Jolla, California • Orange, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 2, 2026, 5:27 AM EDT
Terminated Phase 1 Interventional Results available

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

NCT03705351
View directory record Official record
Conditions
Glioblastoma, Cancer of Brain, Glioblastoma Multiforme, Brain Tumor
Interventions
Tumor Treating Fields, Temozolomide, Radiation Therapy
Device · Drug · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
22 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 2, 2026, 5:27 AM EDT
Terminated Phase 2 Interventional Results available

Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

NCT03903640
View directory record Official record
Conditions
Melanoma With Brain Metastasis
Interventions
Optune, Nivolumab, Ipilimumab
Device · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 2, 2026, 5:27 AM EDT
Active, not recruiting Phase 2 Interventional

Niraparib/TTFields in GBM

NCT04221503
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM
Interventions
Niraparib, Optune, Planned surgical resection
Drug · Device · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 2, 2026, 5:27 AM EDT
Active, not recruiting Not applicable Interventional

Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

NCT01892397
View directory record Official record
Conditions
Brain Cancer
Interventions
Optune (NovoTTF-100A)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 2, 2026, 5:27 AM EDT
Completed No phase listed Observational

Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields

NCT03501134
View directory record Official record
Conditions
Malignant Glioma
Interventions
NovoTTF
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 2, 2026, 5:27 AM EDT
Active, not recruiting Not applicable Interventional

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

NCT03033992
View directory record Official record
Conditions
Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions
Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
Device · Combination Product
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 2, 2026, 5:27 AM EDT
Completed Phase 1 Interventional

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

NCT03232424
View directory record Official record
Conditions
Glioblastoma, Adult
Interventions
NovoTTF-200A, Temozolomide, 3D conformal or intensity modulated radiation therapy (IMRT)
Device · Drug · Radiation
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 2, 2026, 5:27 AM EDT